Results 251 to 260 of about 41,944 (264)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Neuro-Oncology, 2020
Catherine McBain, Anthony J Chalmers
exaly  

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

Investigational New Drugs, 2016
Eric Chen, Derek J Jonker, Lillian L Siu   +2 more
exaly  

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

Annals of Oncology, 2014
Judith Balmana
exaly  

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Lancet, The, 2010
Michael Friedländer, Clare L Scott, Ana Oaknin   +2 more
exaly  

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

European Journal of Clinical Pharmacology, 2020
Maaike A C Bruin, C M Korse, Sabine C Linn   +2 more
exaly  

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Annals of Oncology, 2015
Ian Chau, Eileen M O'Reilly
exaly  

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

Radiotherapy and Oncology, 2015
Annalisa L E Carli, Mark J O'Connor, Jos Jonkers   +2 more
exaly  

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

European Journal of Cancer, 2019
Mark E Robson, Kathryn J Ruddy, Seock-Ah Im   +2 more
exaly  

Olaparib

Reactions Weekly, 2016
openaire   +1 more source

<p>Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date</p>

OncoTargets and Therapy, 2019
Michelle Lightfoot, Kristin Bixel
exaly